Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

469 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.
Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, Vance GH, Dlouhy SR, Baute JA, Cox EA, Wood LL, Srivastava S, Robertson KA, Haut PR, Farag SS, Abonour R, Cornetta K, Cripe LD. Nelson RP Jr, et al. Among authors: schwartz je. Bone Marrow Transplant. 2010 Aug;45(8):1300-8. doi: 10.1038/bmt.2009.348. Epub 2010 Jan 11. Bone Marrow Transplant. 2010. PMID: 20062092
Histological evaluation of acute mucocutaneous graft-versus-host disease in nonmyeloablative hematologic stem cell transplants with an observation predicting an increased risk of progression to chronic graft-versus-host disease.
Bridge AT, Nelson RP Jr, Schwartz JE, Mirowski GW, Billings SD. Bridge AT, et al. Among authors: schwartz je. Am J Dermatopathol. 2007 Feb;29(1):1-6. doi: 10.1097/01.dad.0000246173.96318.0c. Am J Dermatopathol. 2007. PMID: 17284954
Prophylaxis with sirolimus and tacrolimus ± antithymocyte globulin reduces the risk of acute graft-versus-host disease without an overall survival benefit following allogeneic stem cell transplantation.
Rosenbeck LL, Kiel PJ, Kalsekar I, Vargo C, Baute J, Sullivan CK, Wood L, Abdelqader S, Schwartz J, Srivastava S, Abonour R, Robertson MJ, Nelson RP Jr, Cornetta K, Fausel CA, Farag SS. Rosenbeck LL, et al. Biol Blood Marrow Transplant. 2011 Jun;17(6):916-22. doi: 10.1016/j.bbmt.2010.09.017. Epub 2010 Dec 4. Biol Blood Marrow Transplant. 2011. PMID: 20932925 Free article.
A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Srivastava S, Jones D, Wood LL, Schwartz JE, Nelson RP Jr, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Robertson MJ, Farag SS. Srivastava S, et al. Among authors: schwartz je. Biol Blood Marrow Transplant. 2011 Jul;17(7):987-94. doi: 10.1016/j.bbmt.2010.10.016. Epub 2010 Oct 20. Biol Blood Marrow Transplant. 2011. PMID: 20965266 Free article. Clinical Trial.
Phase I trial and pharmacokinetic study of high-dose clofarabine and busulfan and allogeneic stem cell transplantation in adults with high-risk and refractory acute leukemia.
Farag SS, Wood LL, Schwartz JE, Srivastava S, Nelson RP Jr, Robertson MJ, Abonour R, Secrest A, Cox E, Baute J, Sullivan C, Kane K, Jones DR. Farag SS, et al. Among authors: schwartz je. Leukemia. 2011 Apr;25(4):599-605. doi: 10.1038/leu.2010.319. Epub 2011 Jan 21. Leukemia. 2011. PMID: 21252987 Clinical Trial.
Low CD34+ Cell Doses Are Associated with Increased Cost and Worse Outcome after Tandem Autologous Stem Cell Transplantation in Patients with Relapsed or Refractory Germ Cell Tumors.
Hyder MA, Goebel WS, Ervin KD, Schwartz JE, Robertson MJ, Thakrar TC, Albany C, Farag SS. Hyder MA, et al. Among authors: schwartz je. Biol Blood Marrow Transplant. 2018 Jul;24(7):1497-1504. doi: 10.1016/j.bbmt.2018.01.032. Epub 2018 Feb 2. Biol Blood Marrow Transplant. 2018. PMID: 29410296 Free article.
469 results